Rep. Michael Waltz (R-Fla. 6th District), a U.S. Army officer, is defending the president's actions in authorizing a drone strike that killed Gen. Qassem Soleimani last week and told Cheddar the president acted in self-defense, which Waltz said means he did not need to consult Congress first.

"Looking backwards, I'm fine with this strike," said Waltz. "I think the president has a duty if he has actionable intelligence that [Soleimani] is going to continue to kill Americans ⁠— he's operating in the country where he continues to plot and plan those attacks as he has done for decades ⁠— he is a lawful enemy combatant, completely within the president's authority to defend our diplomats and our soldiers."

White House officials have not yet provided any evidence showing a threat, which the president called "imminent," or revealed when an attack was expected. Senator Bob Menendez (D-N.J.), the top Democrat on the Senate Foreign Relations Committee, called on the president to release the intelligence.

Waltz, who is on the Armed Services Committee, said he is heading to the White House this afternoon to "take a look at it, myself."

Some Pentagon officials have said intelligence did not show an imminent attack and that the move was part of Secretary of State Mike Pompeo's push for aggressive action against Iran.

Waltz echoed remarks from Pompeo this morning, who said Soleimani's "long history of attacking Americans and killing people across the Middle East" led to Trump's decision to authorize the drone strike, at least in part.

The congressman also said the strike came "after a long string of Iranian provocations. This is not an escalation, this is a response, and it's a response designed to stop further escalation," similar to Trump's claim that he ordered the strike to stop war, not start it.

"No one in this administration that I've talked to is talking about a D-Day, Normandy style invasion, boots on the ground of Iran," Waltz said, which would necessitate an Authorization for Use of Military Force from Congress. "Self defense is always within the laws of land warfare and within the commander in chief."

Share:
More In Politics
Trump suggests canceling Xi meeting and threatens more tariffs after China restricts key exports
President Donald Trump says “there seems to be no reason” to meet with Chinese leader Xi Jinping as part of an upcoming trip to South Korea after China restricted exports of rare earths needed for American industry. The Republican president suggested Friday he was looking at a “massive increase” of import taxes on Chinese products in response to Xi’s moves. Trump says one of the policies the U.S. is calculating is "a massive increase of Tariffs on Chinese products coming into the United States." A monthslong calm on Wall Street was shattered, with U.S. stocks falling on the news. The Chinese Embassy in Washington hasn't responded to an Associated Press request for comment.
Poll: More Americans think companies benefit from legal immigration
A new poll finds U.S. adults are more likely than they were a year ago to think immigrants in the country legally benefit the economy. That comes as President Donald Trump's administration imposes new restrictions targeting legal pathways into the country. The Associated Press-NORC Center for Public Affairs Research survey finds Americans are more likely than they were in March 2024 to say it’s a “major benefit” that people who come to the U.S. legally contribute to the economy and help American companies get the expertise of skilled workers. At the same time, perceptions of illegal immigration haven’t shifted meaningfully. Americans still see fewer benefits from people who come to the U.S. illegally.
Tylenol maker rebounds a day after unfounded claims about its safety
Shares of Tylenol maker Kenvue are bouncing back sharply before the opening bell a day after President Donald Trump promoted unproven and in some cases discredited ties between Tylenol, vaccines and autism. Trump told pregnant women not to use the painkiller around a dozen times during the White House news conference Monday. The drugmaker tumbled 7.5%. Shares have regained most of those losses early Tuesday in premarket trading.
Load More